Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare and often very severe diseases occur when the cell's energy provider, the mitochondria, do not function properly.
The company is focused on two projects. KL1333, a powerful NAD⁺ regulator, is in clinical development and has been granted orphan drug designation in Europe and the US. NV354, an energy replacement (succinate) therapy, will enter the clinic in 2022.
2000
Served areaWorldwide
HeadquartersScheeletorget 1, 22381 Lund – Sweden
Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
---|---|---|---|---|
Assets | N/A | 98,957,000.00 | 58,918,000.00 | 183,829,000.00 |
Noncurrent Assets | N/A | 35,800,000.00 | 34,664,000.00 | 34,013,000.00 |
Property Plant And Equipment | N/A | 384,000.00 | 60,000.00 | 908,000.00 |
Other Intangible Assets | N/A | 1,344,000.00 | 1,210,000.00 | 1,075,000.00 |
Investments In Associates Accounted For Using Equity Method | N/A | 13,101,000.00 | 13,101,000.00 | 13,101,000.00 |
Current Assets | N/A | 63,157,000.00 | 24,254,000.00 | 149,816,000.00 |
Other Current Receivables | N/A | 928,000.00 | 912,000.00 | 849,000.00 |
Cash and cash equivalents | 58,319,000.00 | 61,643,000.00 | 22,339,000.00 | 66,392,000.00 |
Current Investments | N/A | N/A | 0.00 | 78,949,000.00 |
Equity And Liabilities | N/A | 98,957,000.00 | 58,918,000.00 | 183,828,000.00 |
Equity | 76,089,000.00 | 88,656,000.00 | 41,528,000.00 | 164,287,000.00 |
Issued Capital | N/A | 14,817,000.00 | 20,150,000.00 | 52,815,000.00 |
Retained Earnings | N/A | -586,802,000.00 | -709,879,000.00 | -794,582,000.00 |
Other Reserves | N/A | 616,000.00 | 688,000.00 | 833,000.00 |
Additional Paidin Capital | N/A | 660,025,000.00 | 730,560,000.00 | 905,221,000.00 |
Equity Attributable To Owners Of Parent | N/A | 88,656,000.00 | 41,519,000.00 | 164,287,000.00 |
Noncontrolling Interests | N/A | 0.00 | 9,000.00 | 0.00 |
Liabilities | N/A | 10,301,000.00 | 17,390,000.00 | 19,541,000.00 |
Noncurrent Liabilities | N/A | 92,000.00 | 0.00 | 534,000.00 |
Other Noncurrent Liabilities | N/A | 92,000.00 | 0.00 | 534,000.00 |
Current Liabilities | N/A | 10,209,000.00 | 17,390,000.00 | 19,007,000.00 |
Trade And Other Current Payables To Trade Suppliers | N/A | 4,201,000.00 | 9,616,000.00 | 4,860,000.00 |
Current Accruals And Current Deferred Income Including Current Contract Liabilities | N/A | N/A | 7,497,000.00 | 13,599,000.00 |
Other Current Liabilities | N/A | 675,000.00 | 277,000.00 | 548,000.00 |
Line item in (sek) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
---|---|---|---|
Revenue | 216,000.00 | 151,000.00 | 31,000.00 |
Other Income | 1,648,000.00 | 0.00 | 1,716,000.00 |
Employee Benefits Expense | 13,305,000.00 | 16,844,000.00 | 14,028,000.00 |
Depreciation Amortisation And Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss | 2,558,000.00 | 2,764,000.00 | 2,610,000.00 |
Other Expense By Nature | 0.00 | 330,000.00 | 0.00 |
Profit Loss From Operating Activities | -60,071,000.00 | -123,482,000.00 | -83,190,000.00 |
Finance Income | N/A | 0.00 | 392,000.00 |
Finance Costs | 30,000.00 | 12,000.00 | 2,764,000.00 |
Profit Loss Before Tax | -59,994,000.00 | -123,494,000.00 | -85,264,000.00 |
Income Tax Expense Continuing Operations | 0.00 | 4,000.00 | 0.00 |
Profit (loss) | -59,994,000.00 | -123,498,000.00 | -85,264,000.00 |
Profit Loss Attributable To Owners Of Parent | -59,989,000.00 | -123,492,000.00 | -85,262,000.00 |
Profit Loss Attributable To Noncontrolling Interests | -5,000.00 | -6,000.00 | -2,000.00 |
Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
---|---|---|---|---|
Profit (loss) | N/A | -59,994,000.00 | -123,498,000.00 | -85,264,000.00 |
Adjustments For Depreciation And Amortisation Expense | N/A | 2,558,000.00 | 2,660,000.00 | 2,610,000.00 |
Adjustments For Unrealised Foreign Exchange Losses Gains | N/A | 0.00 | -7,000.00 | 192,000.00 |
Adjustments For Sharebased Payments | N/A | 0.00 | 415,000.00 | 551,000.00 |
Adjustments For Undistributed Profits Of Associates | N/A | -107,000.00 | 0.00 | -298,000.00 |
Interest Paid Classified As Operating Activities | N/A | 30,000.00 | 12,000.00 | 25,000.00 |
Interest Received Classified As Operating Activities | N/A | N/A | 0.00 | 392,000.00 |
Cash Flows From Used In Operating Activities | N/A | -67,558,000.00 | -114,075,000.00 | -159,560,000.00 |
Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 0.00 | 65,000.00 | 23,000.00 |
Purchase Of Intangible Assets Classified As Investing Activities | N/A | 1,407,000.00 | 1,024,000.00 | 882,000.00 |
Cash Flows From Used In Investing Activities | N/A | -1,407,000.00 | -1,089,000.00 | -905,000.00 |
Proceeds From Issuing Shares | N/A | 72,564,000.00 | 75,868,000.00 | 180,364,000.00 |
Payments Of Lease Liabilities Classified As Financing Activities | N/A | 269,000.00 | 92,000.00 | 170,000.00 |
Cash Flows From Used In Financing Activities | N/A | 72,295,000.00 | 75,792,000.00 | 204,417,000.00 |
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | 3,330,000.00 | -39,372,000.00 | 43,952,000.00 |
Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -6,000.00 | 68,000.00 | 101,000.00 |
Cash and cash equivalents | 58,319,000.00 | 61,643,000.00 | 22,339,000.00 | 66,392,000.00 |
Please note that some sums might not add up.
Date | Trading entity / Person | Association | Trade type | Volume |
---|---|---|---|---|
13.07.23 | David Laskow-Pooley | Other | Buy | SEK 11,664.58 |
13.07.23 | David Laskow-Pooley | Other | Buy | SEK 8,151.00 |
13.07.23 | David Laskow-Pooley | Other | Buy | SEK 7,807.86 |
13.07.23 | David Laskow-Pooley | Other | Buy | SEK 3,267.20 |
13.07.23 | David Laskow-Pooley | Other | Buy | SEK 2,588.47 |
13.07.23 | David Laskow-Pooley | Other | Buy | SEK 2,479.40 |
13.07.23 | David Laskow-Pooley | Other | Buy | SEK 2,474.86 |
13.07.23 | David Laskow-Pooley | Other | Buy | SEK 2,469.50 |
13.07.23 | David Laskow-Pooley | Other | Buy | SEK 2,456.96 |
13.07.23 | David Laskow-Pooley | Other | Buy | SEK 2,451.85 |
SE0002575340
LEI5493005YV22OTMUHZ183
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.